Prognosis
Intercept Tries to Outrun Pharma in Race for the Next Blockbuster
The company’s liver-disease drug is ahead of the competition. That may not be enough to control a potentially vast market.
Doctors say that getting people who are overweight and have become ill with NASH to change their lifestyles can be an uphill battle.
Photographer: Justin Sullivan/Getty Images North AmericaThis article is for subscribers only.
Want more news about the future of health care? Sign up here for Bloomberg’s Prognosis newsletter to get great stories delivered to your inbox every Thursday.
Nearly two decades ago, doctor and venture capitalist Mark Pruzanski learned of a liver disease that could be lurking undetected in the bodies of tens of millions of people.